Katherine Zarroli
CLIN AST PROF
JX-NEUROLOGY-JACKSONVILLE
GRANTS
- GRANT“A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures, with Open-label Extension Epilepsy” (SHINE)Biohaven Pharmaceuticals15 Aug 2024 - 15 Aug 2029
- GRANT“A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy”Biohaven Pharmaceuticals2 Jul 2024 - 2 Jul 2029
- GRANTA Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset EpilepsyBiohaven Pharmaceuticals21 Feb 2024 - 21 Feb 2029
- GRANTSAFETY AND THERAPEUTIC MEASURES OF TRANSCRANIAL CATHODAL DIRECT CURRENT STIMULATION (TDCS) IN PATIENTS WITH REFRACTORY FOCAL EPILEPSYNeuroelectrics USA7 Jun 2022 - 7 Jun 2027
- GRANTPilot Study of Add-On Fycompa (peramapanel) Treatment for Catamenial EpilepsyCatalyst Pharmaceuticals1 Nov 2021 - 29 Jan 2024
- GRANTA Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut SyndromeEisai Corporation29 Aug 2020 - 29 Aug 2025